Establishment Labs Holdings (Nasdaq:ESTA) - Aandelenkoers, Nieuws & Analyse

ESTA Overzicht aandelen

Establishment Labs Holdings Inc, een medisch technologiebedrijf, produceert en verkoopt medische hulpmiddelen voor esthetische en reconstructieve plastische chirurgie. Meer informatie

ESTA fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	2/6
Dividenden	0/6

Beloningen

Verhandeld tegen 21.4% onder onze schatting van de reële waarde

De winst zal naar verwachting met 49.22% per jaar groeien

Risicoanalyse

Volatiele aandelenkoers in de afgelopen 3 maanden

Aandeelhouders zijn het afgelopen jaar verwaterd

Establishment Labs Holdings Inc. Concurrenten

STAAR Surgical

NasdaqGM:STAA

US$1.3b

Bioventus

NasdaqGS:BVS

US$765.5m

Meridian Bioscience

NasdaqGS:VIVO

US$1.5b

Embecta

NasdaqGS:EMBC

US$797.4m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Establishment Labs Holdings
Historische aandelenkoersen
Huidige aandelenkoers	US$43.08
52 Week Hoogtepunt	US$60.12
52 Week Laag	US$22.05
Bèta	1.21
11 maand verandering	-3.49%
3 maanden verandering	-6.89%
1 Jaar Verandering	82.77%
33 jaar verandering	-33.66%
5 jaar verandering	82.85%
Verandering sinds IPO	74.06%

Recent nieuws en updates

Recent updates

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Sep 23

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Aug 11

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Jul 23

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Apr 17

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Dec 14

Establishment Labs drops 18% after new short report from Hindenburg Research

Oct 19

Establishment Labs: Flat Earnings, Return On Investment Keep Buyers At Bay

Sep 24

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Sep 04

Establishment Labs started at buy at B Riley on breast implants

Aug 24

Rendement voor aandeelhouders

	ESTA	US Medical Equipment	US Markt
7D	14.0%	1.5%	2.2%
1Y	82.8%	20.8%	31.6%

Rendement versus industrie: ESTA overtrof de US Medical Equipment industrie, die het afgelopen jaar een rendement 20.8 % opleverde.

Rendement versus markt: ESTA overtrof de US markt, die het afgelopen jaar een rendement opleverde van 31.6 %.

Prijsvolatiliteit

Is ESTA's price volatile compared to industry and market?
ESTA volatility
ESTA Average Weekly Movement	10.1%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van ESTA is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 10% ) van ESTA is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2004	933	Juan Chacon Quiros	www.establishmentlabs.com

Establishment Labs Holdings Inc., een medisch technologiebedrijf, produceert en verkoopt medische hulpmiddelen voor esthetische en reconstructieve plastische chirurgie. Het bedrijf biedt voornamelijk met siliconengel gevulde borstimplantaten aan onder de merknaam Motiva Implants. Het bedrijf levert ook Motiva Ergonomix en Motiva Ergonomix2 zwaartekrachtgevoelige ronde borstimplantaten gevuld met zachte siliconengel; en Motiva Flora Tissue Expander, een borstweefselexpander.

Establishment Labs Holdings Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Establishment Labs Holdings zich tot de beurswaarde?
ESTA fundamentele statistieken
Marktkapitalisatie	US$1.21b
Inkomsten(TTM)	-US$70.61m
Inkomsten(TTM)	US$153.07m

7.9x

P/S-verhouding

-17.1x

Koers/Winstverhouding

Is ESTA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ESTA resultatenrekening (TTM)
Inkomsten	US$153.07m
Kosten van inkomsten	US$53.45m
Brutowinst	US$99.62m
Overige uitgaven	US$170.23m
Inkomsten	-US$70.61m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-2.52
Brutomarge	65.08%
Nettowinstmarge	-46.13%
Schuld/Eigen Vermogen Verhouding	594.2%

Hoe presteerde ESTA op de lange termijn?

Bekijk historische prestaties en vergelijking

ESTA Overzicht aandelen

Beloningen

Risicoanalyse

Establishment Labs Holdings Inc. Concurrenten

NasdaqGM:STAA

US$1.3b

NasdaqGS:BVS

US$765.5m

NasdaqGS:VIVO

US$1.5b

NasdaqGS:EMBC

US$797.4m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Establishment Labs Holdings Inc. has filed a Follow-on Equity Offering in the amount of $49.999555 million.

Establishment Labs Holdings Inc. Updates Revenue Guidance for 2024

Establishment Labs Holdings Inc. to Report Q3, 2024 Results on Nov 07, 2024

Establishment Labs Holdings Inc. Announces the First Patients in the United States Have Successfully Undergone Breast Augmentation with Motiva Implants

New minor risk - Share price stability

Establishment Labs Holdings Inc. Receives U.S. FDA Approval for Motiva Implants

Recent updates

Establishment Labs Holdings Inc. has filed a Follow-on Equity Offering in the amount of $49.999555 million.

Establishment Labs Holdings Inc. Updates Revenue Guidance for 2024

Establishment Labs Holdings Inc. to Report Q3, 2024 Results on Nov 07, 2024

Establishment Labs Holdings Inc. Announces the First Patients in the United States Have Successfully Undergone Breast Augmentation with Motiva Implants

New minor risk - Share price stability

Establishment Labs Holdings Inc. Receives U.S. FDA Approval for Motiva Implants

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

No longer forecast to breakeven

Consensus EPS estimates fall by 25%

Earnings Release: Here's Why Analysts Cut Their Establishment Labs Holdings Inc. (NASDAQ:ESTA) Price Target To US$59.86

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q2, 2024 Results on Aug 06, 2024

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Founder notifies of intention to sell stock

Insufficient new directors

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q1, 2024 Results on May 08, 2024

Establishment Labs Holdings Inc., Annual General Meeting, May 24, 2024

Establishment Labs Holdings Inc. announced delayed annual 10-K filing

Price target increased by 10% to US$52.86

Full year 2023 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2024

Establishment Labs Holdings Inc. to Report Q4, 2023 Results on Feb 28, 2024

Establishment Labs: Catalysts Supporting A Perky Outlook

Establishment Labs Holdings Inc. announced that it has received $49.999102 million in funding from a group of investors

Establishment Labs Holdings Inc. announced that it expects to receive $50 million in funding

Establishment Labs Holdings Inc. Announces First U.S. Commercial Procedure with Motiva Flora Tissue Expander

Forecast to breakeven in 2026

Is Establishment Labs Holdings (NASDAQ:ESTA) A Risky Investment?

Chairman of the Board recently bought US$110k worth of stock

Chairman of the Board exercised options to buy US$5.8m worth of stock.

Consensus revenue estimates fall by 18%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

New minor risk - Share price stability

Establishment Labs Holdings Inc. to Report Q3, 2023 Results on Nov 07, 2023

Establishment Labs Announces FDA Clearance of Motiva Flora Smoothsilk Tissue Expander

Price target decreased by 7.7% to US$89.38

Est Establishment Labs Holdings Inc. Announces Two-Year Mia Femtech Clinical Results and the Launch of Zen at 8th World Symposium on Ergonomic Implants

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Year 2023

Is Establishment Labs Holdings (NASDAQ:ESTA) Using Too Much Debt?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Establishment Labs Holdings Inc. to Report Q2, 2023 Results on Aug 08, 2023

Establishment Labs Holdings Inc. Provides Revenue Guidance for the Fiscal Year 2023

First quarter 2023 earnings released: US$0.48 loss per share (vs US$0.24 loss in 1Q 2022)

Shareholders Should Be Pleased With Establishment Labs Holdings Inc.'s (NASDAQ:ESTA) Price

Insider recently sold US$254k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Establishment Labs Holdings Inc. to Report Q4, 2022 Results on Feb 27, 2023

Establishment Labs Holdings Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Fiscal Year Ended December 31, 2022

Establishment Labs Holdings (NASDAQ:ESTA) Is Carrying A Fair Bit Of Debt

Establishment Labs Holdings Inc. Appoints Paul D. Rodio as Chief Operating Officer

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Establishment Labs Holdings Inc. Provides Earnings Guidance for the Year 2022

Establishment Labs Holdings Inc. to Report Q3, 2022 Results on Nov 07, 2022

Establishment Labs drops 18% after new short report from Hindenburg Research

Price target increased to US$97.40